United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Biotech Giants

In the competitive world of biotechnology, understanding spending patterns can offer valuable insights into a company's strategic priorities. Over the past decade, United Therapeutics Corporation and Bio-Techne Corporation have demonstrated distinct approaches to their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, United Therapeutics consistently outspent Bio-Techne, with its SG&A expenses peaking at approximately 487 million in 2022, a 28% increase from 2014. In contrast, Bio-Techne's SG&A expenses grew more steadily, reaching around 397 million in 2024, marking a significant 554% increase from its 2014 figures. This divergence highlights United Therapeutics' aggressive investment in administrative capabilities, while Bio-Techne's gradual increase suggests a more conservative approach. Notably, data for United Therapeutics in 2024 is missing, leaving room for speculation on its future spending trajectory. These patterns reflect broader strategic decisions that could influence their competitive positioning in the biotech industry.